FDA Approves MORPHINE SULFATE — SpecGx LLC
SpecGx LLC received FDA approval for ANDA076438, marking the launch of generic morphine sulfate (oral) in the U.S. market. This move is expected to intensify pricing pressure on the branded opioid product and expand access to affordable treatment options.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed